Company K Partners

Company K Partners is a principal investment firm based in Gyeonggi-do, South Korea, established in 2006. The firm focuses on investments in various industries, including cultural content, electronic components, computer technology, machinery, broadcasting, arts, sports, and leisure. While primarily investing in South Korea, particularly in the regions of Seoul, Gyeongnam, and Gyeonggi, Company K Partners also seeks opportunities in the information technology and healthcare sectors.

Jae Won D

Principal

241 past transactions

MADDE

Series A in 2025
MADDE possesses the technology to use silicon carbide powder in 3D printers to create various forms, which opens up a multitude of possibilities in the manufacturing sector.

Prazer Therapeutics

Series B in 2025
Prazer Therapeutics is a biotechnology company dedicated to developing novel therapeutics for patients suffering from intractable diseases, particularly focusing on neurodegenerative and refractory inflammatory conditions. The company employs innovative drug design approaches, including rational molecular drug design and next-generation protein degradation technology, to create effective treatments. By leveraging these advanced platforms, Prazer Therapeutics aims to address significant unmet medical needs and enhance the treatment landscape for challenging health issues.

Imagoworks

Series C in 2024
Imagoworks offers a Web-based dental CAD solution using AI, streamlining the digital workflow for dental professionals. Imagoworks currently offers Dentbird Crown, which automatically generates optimal crown designs with a single click and without any software installation required.

Hyperaccel

Series A in 2024
HyperAccel provides hardware solutions for developing AI applications.

BaroPharm

Venture Round in 2024
Baropharm is an online e-commerce platform focused on selling pharmaceutical products to enhance individual care. It operates a pharmacy management system that streamlines the ordering process for pharmacies by consolidating access to multiple wholesale sites into a single integrated platform. This approach allows pharmacies to efficiently manage their drug orders, simplifying the procurement of medicines and improving operational efficiency. Through its innovative platform, Baropharm aims to support pharmacies in delivering better healthcare services.

Qutope

Series A in 2024
QuTope is a manufacturer specializing in chemical and biomaterials, with a focus on laser-based isotope separation and production technologies. The company develops a platform that produces isotope materials for various applications, including biochemical, nanoelectronics, and quantum technologies. By providing affordable isotopic products, QuTope aims to support advancements in quantum sensors and quantum computing, catering to clients in multiple high-tech fields.

Makestar

Series D in 2024
Makestar is a platform dedicated to K-culture content, connecting Hallyu stars with fans across the globe. It serves as a music crowdfunding platform that supports various projects related to Korean pop music, allowing artists and production companies to share their creative visions. By fostering interactions between fans and celebrities, Makestar enables fans to engage directly in the content creation process and facilitates the international advancement of K-pop artists. This unique model not only strengthens the bond between fans and artists but also enhances the global reach of Korean entertainment.

Bio Design Lab

Series B in 2024
Bio Design Lab is a biotechnology company focused on the development of biopharmaceutical products. It specializes in creating gene, cell, and immuno-therapies through advanced systems-level genetic and genomic design strategies. By leveraging these innovative approaches, the company aims to accelerate the production of highly effective biopharmaceuticals for the treatment of various diseases, thereby enhancing the capabilities of healthcare organizations.

Diden Robotics

Seed Round in 2024
Diden Robotics, a company specializing in industrial robot solutions, Diden Robotics is developing a quadruped robot for iron environments, providing automated inspection and work solutions introduced the Ascension Robot technology to streamline complex and dangerous work processes. The robot can work over complex obstacles, reducing human casualties and increasing efficiency.

BaroPharm

Venture Round in 2024
Baropharm is an online e-commerce platform focused on selling pharmaceutical products to enhance individual care. It operates a pharmacy management system that streamlines the ordering process for pharmacies by consolidating access to multiple wholesale sites into a single integrated platform. This approach allows pharmacies to efficiently manage their drug orders, simplifying the procurement of medicines and improving operational efficiency. Through its innovative platform, Baropharm aims to support pharmacies in delivering better healthcare services.

Velymonkeys

Series B in 2024
Blimonkids has created and run its own retail platform to aid the expansion of Korean cosmetics in India. In particular, it offers a one-stop service for the introduction of Korean beauty products into India, distribution, and sales, as well as marketing and sales, through its own mall, Maccaron.

EYEQ Lab

Series B in 2024
EYEQ Lab is an engineering service company that specializes in the development and manufacturing of power semiconductors. The company aims to revolutionize the power semiconductor industry by applying its expertise and advanced technologies to various sectors. Its products cater to a range of applications, including solar cells, autonomous vehicles, high-speed battery chargers, medical equipment, and aerospace. EYEQ Lab's focus on innovation and skilled engineering enables its customers to stay at the forefront of power semiconductor technologies.

Space Lintech

Series A in 2024
Space Lintech provides novel medical research, development, and manufacture in the microgravity environment of satellites and space stations.

Meditherapy

Series A in 2024
Meditherapy Co. is a retailer specializing in health and beauty products, particularly focused on skincare. The company offers a platform that provides a wide range of skincare items, including eye creams, wrinkle rollers, face masks, and serums. By consolidating various skincare needs into a single platform, Meditherapy aims to simplify the shopping experience for customers seeking quality beauty products for both the face and body.

Raion Robotics

Seed Round in 2024
Raion Robotics manufactures walking robots for industrial applications and offers prospects in potential industries such as defense, construction, and logistics.

Wirobotics

Series A in 2024
Wirobotics develops wearable robot technology aimed at enhancing musculoskeletal health and reducing physical strain on the body. Their innovative robotic products utilize flexible mechanisms and high-performance actuators, allowing them to closely conform to the user's body. By incorporating task monitoring and analysis, Wirobotics quantifies labor intensity and workload, helping organizations improve workplace safety and efficiency. The company's solutions are designed to promote active motion while ensuring that physical demands are managed effectively, thus fostering a healthier work environment.

AlgoCare

Series A in 2024
Algocare is an AI-driven healthcare startup that provides specialized Nutrition as a Service (NaaS) to individuals and organizations. The company has developed a unique nutrition management appliance designed to deliver personalized nutrient recommendations. This home appliance continuously analyzes health data to accurately assess the type and quantity of nutrients needed, allowing users to monitor and improve their health effectively. Through its innovative approach, Algocare aims to enhance nutritional awareness and management for its customers.

Mediquitous

Series D in 2024
Mediquitous is a natural health and beauty company focused on enhancing individuals' quality of life through its diverse range of products. The company specializes in manufacturing skincare and food items, including beauty patches, jelly food, and various healing products. By offering these innovative solutions, Mediquitous aims to provide customers with effective and convenient options for maintaining their beauty and well-being.

Easytem

Venture Round in 2024
Easytem is a manufacturing company that designs and develops medical devices to enhance skin and health in users.

StudyMax

Series C in 2024
StudyMax is a Korean company that specializes in online English language learning for non-English speaking students. The platform provides a variety of interactive tools, tutorials, and study programs designed to enhance the learning experience. Users can engage with 11 different educational methods, including game-like elements such as badges and interactive learning features. The Max online English learning program is accessible on both PCs and mobile devices, ensuring flexibility for users. Additionally, the application can be downloaded from the iTunes store, allowing learners to study anytime and anywhere. With a focus on vibrant digital content, StudyMax incorporates videos, games, and animations to create an engaging and effective learning environment.

Novorex

Series A in 2023
Novorex focuses on developing small-molecule drugs aimed at treating oncology and neurology diseases. The company employs advanced technologies, including artificial intelligence, to enhance drug development processes. By integrating biophysical analysis with in vitro and in vivo assays, Novorex aims to improve the efficacy of its new treatments, ultimately providing patients with innovative solutions for cancer and central nervous system disorders.

Getcha

Series B in 2023
Getcha operates as a comprehensive online platform for car purchasing, long-term rentals, leasing, test rides, and car consulting. The company connects buyers with sellers through a comparison shopping service, allowing consumers to access a network of dealerships and obtain multiple price quotes. This transparency in transaction pricing empowers consumers to make informed decisions while enabling sellers to concentrate on potential buyers. By streamlining the car buying and renting process, Getcha aims to enhance the overall experience for both consumers and sellers in the automotive market.

CareMedi

Series B in 2023
Caremedi is a healthcare company focused on developing innovative medical devices, particularly a wearable drug pump designed to enhance the quality of life for individuals with diabetes. The company offers a range of healthcare products, including medical equipment, nebulizers, aspirators, and massagers, allowing consumers to conveniently order these items from home. By prioritizing user-friendly solutions, Caremedi aims to improve the lifestyles of its customers through accessible and effective healthcare technology.

Medipixel

Series B in 2023
Medipixel, Inc., founded in 2017 and based in Seoul, South Korea, specializes in developing artificial intelligence-based diagnostic software and semi-autonomous surgical tools for lung cancer and cardiac disease interventions. The company employs a team of experts in computer vision, deep learning, and reinforcement learning, collaborating with leading healthcare institutions to enhance diagnostic and surgical processes. Medipixel offers several innovative solutions, including an AI-based diagnosis tool that assists doctors in identifying lesions during coronary angiography, a guide and planning solution that visualizes hidden coronary artery segments to facilitate guidewire manipulation, and an automated navigation engine that optimizes robotic control for surgical procedures. By integrating advanced AI technologies, Medipixel aims to improve the quality of medical care and patient outcomes in the field of surgery.

Velymonkeys

Series A in 2023
Blimonkids has created and run its own retail platform to aid the expansion of Korean cosmetics in India. In particular, it offers a one-stop service for the introduction of Korean beauty products into India, distribution, and sales, as well as marketing and sales, through its own mall, Maccaron.

Catch Table

Series D in 2023
Catch Table is a restaurant reservation management platform that offers online reservation services to customers. It allows users to filter restaurant options based on various criteria, including date, number of guests, cost, food category, and table type. The platform also provides additional information such as valet parking and corkage services, making it easier for customers to find the right dining experience. By enabling real-time reservations, Catch Table streamlines the process of booking tables in restaurants, facilitating a more efficient dining experience for both customers and restaurant operators.

Gwanak Analog

Series A in 2023
Gwanak Analog is a company specializing in the design and supply of high-performance power and analog system-on-chip (SoC) products. Its offerings cater to various sectors, including industrial, telecommunications, automotive, and consumer applications. By integrating advanced power semiconductor design technology with digital signal processing, Gwanak Analog develops efficient analog and power system semiconductors. This approach helps clients minimize energy consumption in their systems while providing environmentally friendly and compact solutions.

Fadu

Venture Round in 2023
FADU Inc. is a fabless semiconductor company based in Seoul, South Korea, with an additional office in Mountain View, California. Founded in 2015, FADU specializes in the design and manufacture of memory and storage solutions, focusing on innovative Flash storage technology. The company has developed products such as the FADU Annapurna and FADU Bravo SSD controllers, aimed at addressing the increasing demands for data storage in enterprise datacenters. With a team comprising talented architects, ASIC experts, and seasoned SSD engineers, FADU aims to introduce next-generation storage products that stand out in a rapidly evolving industry. The company is dedicated to advancing Flash storage architecture and supply chain solutions to meet the diverse needs of modern data environments.

Path

Venture Round in 2023
Path provides an AI platform for managing study habits. The startup employs deep learning-based to give non-face-to-face real-time academy lectures for middle and high schools, with the goal of changing the digital education platform.

TCELLOGY

Venture Round in 2023
Tcellogy specializes in the development of personalized cancer vaccines designed to stimulate T-cell responses against neoepitopes. By focusing on precision medicine, the company enhances the quality of life for cancer patients through the creation of patient-specific vaccines. Tcellogy establishes a comprehensive T cell-related information database at the Omics level, which aids in the precise prediction of neoantigen epitopes. This innovative approach enables more tailored treatment options, allowing patients to better assess their health while receiving targeted therapies aimed at their unique cancer profiles.

Novorex

Venture Round in 2023
Novorex focuses on developing small-molecule drugs aimed at treating oncology and neurology diseases. The company employs advanced technologies, including artificial intelligence, to enhance drug development processes. By integrating biophysical analysis with in vitro and in vivo assays, Novorex aims to improve the efficacy of its new treatments, ultimately providing patients with innovative solutions for cancer and central nervous system disorders.

Boostimmune

Venture Round in 2023
Boostimmune is a biotechnology company focused on developing antibody-based therapies to address unmet needs in oncology by enhancing the immune response against cancer. The company is dedicated to researching and developing innovative immuno-oncology drugs that target myeloid-derived suppressor cells (MDSCs), which are known to inhibit the immune system's ability to combat cancer cells. By modulating these immune suppressor cells, Boostimmune aims to increase the activity and frequency of T cells, ultimately improving the body's capacity to eliminate tumors. The team at Boostimmune is composed of industry experts committed to overcoming the challenges of cancer treatment and advancing novel anti-cancer therapies.

Likey

Venture Round in 2023
Likey develops a platform for creators to connect with fans. The platform of the company provides monthly membership payments, a fan-exclusive community, an online class/seminar, customized content, and live video fan meetings, allowing customers to be social and meet their admirers.

Illimis Therapeutics

Venture Round in 2023
Illimis Therapeutics is a biotechnology company focused on developing innovative treatments for neurodegenerative diseases, particularly Alzheimer's disease. The company utilizes a chimeric fusion protein platform to create novel therapeutic options aimed at addressing the unmet medical needs in the treatment of degenerative brain conditions. By leveraging their specialized fusion protein technology, Illimis Therapeutics aims to provide new modalities for patients, enhancing the healthcare industry's ability to combat these challenging diseases.

S&E bio

Series A in 2022
S&E Bio is a biopharmaceutical company dedicated to developing cell therapies specifically designed to treat neurological disorders. The company focuses on creating safe and effective treatments using stem cell-derived extracellular vesicles. Its innovative approach targets various conditions, including acute stroke, moyamoya disease, chronic stroke, dementia, and cognitive disorders. By leveraging mesenchymal stem cell-derived therapeutics, S&E Bio aims to provide advanced treatment options for patients suffering from these challenging and often incurable diseases.

S&E bio

Venture Round in 2022
S&E Bio is a biopharmaceutical company dedicated to developing cell therapies specifically designed to treat neurological disorders. The company focuses on creating safe and effective treatments using stem cell-derived extracellular vesicles. Its innovative approach targets various conditions, including acute stroke, moyamoya disease, chronic stroke, dementia, and cognitive disorders. By leveraging mesenchymal stem cell-derived therapeutics, S&E Bio aims to provide advanced treatment options for patients suffering from these challenging and often incurable diseases.

Imagoworks

Series B in 2022
Imagoworks offers a Web-based dental CAD solution using AI, streamlining the digital workflow for dental professionals. Imagoworks currently offers Dentbird Crown, which automatically generates optimal crown designs with a single click and without any software installation required.

Balaan

Series C in 2022
Balaan is an online marketplace that specializes in providing access to luxury fashion products, including clothing, accessories, and jewelry from renowned brands. By partnering with local boutiques in Europe, Balaan ensures that customers can receive the latest luxury items within three days at competitive prices, making high-end fashion more accessible. The platform aims to cater to both men and women, offering a diverse selection of multi-branded goods that appeal to fashion enthusiasts looking for quality and affordability.

Select Star

Series A in 2022
Select Star is a data platform for AI technology that offers dataset building, storage, and analysis services.

Datumo

Series A in 2022
Datumo, formerly known as SelectStar Inc., specializes in a cloud-based artificial intelligence data production platform. The company has developed an application called Cash Mission, which collects and analyzes data while rewarding users for their contributions. By connecting corporate clients with a network of crowd-workers, Datumo aims to address the challenges of obtaining accurate data for AI applications. The platform not only facilitates this connection but also emphasizes the importance of quality and cost-efficiency in data production. Founded in 2018 and headquartered in South Korea, Datumo continues to innovate in the field of mobile crowd-sourcing to enhance data collection processes for enterprises.

Fainders.AI

Series A in 2022
Fainders.AI specializes in developing unmanned store technology that utilizes computer vision and artificial intelligence to create a checkout-free shopping experience. Their innovative solution enhances convenience for customers while simultaneously increasing profitability for store owners and distributors. By focusing on retail automation, Fainders.AI addresses the challenges associated with traditional in-store shopping, eliminating the need for costly sensor-based hardware installations. This technology allows for a seamless shopping experience, enabling clients to optimize their operations in offline retail environments.

LUNASOFT

Venture Round in 2022
LUNASOFT INC. is a South Korean company founded in 2016, specializing in the development of chatbots and integrated management platforms aimed at enhancing customer support. The company offers a range of solutions, including Luna Plus, a courier exchange platform; Luna Plus Mobile, which facilitates real-time business consultations; and Luna Plus CTI, a customer counseling platform that combines phone and intelligent chat counseling. Additionally, LUNASOFT develops customer consultation chatbots tailored for popular messaging platforms such as Naver and Kakao, primarily catering to e-commerce businesses. Based in Seoul, LUNASOFT is focused on providing innovative chat solutions to improve customer interaction and support processes.

Coinvestor

Series A in 2022
To be the world’s most engaging investment platform for digital assets, Coinvestor provides an interactive digital space for investors and traders seeking profit-making opportunities from digital assets through a seamless and secure service. Coinvestor believes that running a transparent operation, enhancing investment processes, and creating a collaborative environment set it apart from other crypto-investment platforms. On Coinvestor, all crypto-market players can access insights, share strategies, and monetize expertise, feeling assured at any time. Join us in building this journey.

BC Labs

Series A in 2022
BC Labs is a blockchain development and cryptocurrency investment banking company that focuses on innovating investment strategies. The company has created a user-friendly platform that serves as a marketplace for cryptocurrency investment strategies. This platform enables users to purchase and implement trading strategies crafted by investment experts, specifically tailored for the volatile digital asset market. By facilitating the cloning and development of these strategies, BC Labs aims to support both blockchain and crypto traders in navigating the complexities of digital asset investments.

Innospace

Series B in 2022
Innospace is an aerospace and defense company focused on developing hybrid rocket-powered small satellite launch vehicles. The company aims to provide cost-effective, low-latency, and environmentally friendly launch services tailored for the small satellite market. By utilizing innovative hybrid rocket technology, Innospace is committed to delivering reliable solutions for satellite deployment, catering to the increasing demand for efficient access to space.

Jaranda

Series B in 2022
Jaranda is a platform designed to support working parents by providing educational services for children. It addresses the challenges of accessing reliable childcare and education information, which often relies on personal networks. The platform connects parents, teachers, and students, utilizing analytics to match students with appropriate educators. Additionally, Jaranda offers regular visit services and lifecycle management, ensuring that children and pre-teens receive the necessary educational support in a convenient and efficient manner. This approach helps families discover and engage with educational opportunities tailored to their needs.

Catch Table

Series C in 2022
Catch Table is a restaurant reservation management platform that offers online reservation services to customers. It allows users to filter restaurant options based on various criteria, including date, number of guests, cost, food category, and table type. The platform also provides additional information such as valet parking and corkage services, making it easier for customers to find the right dining experience. By enabling real-time reservations, Catch Table streamlines the process of booking tables in restaurants, facilitating a more efficient dining experience for both customers and restaurant operators.

Spark Biopharma

Series C in 2022
SPARK BioPharma Co., Ltd. was established in Seoul National University in January 2016 based on the unique drug molecule diversity technology, the image-based screening technology using the unique fluorescent skeleton probe, and the target protein identification technology in the initial drug development stage. We are currently exploring and developing new drug candidates using these three core technologies, and we will continue to accelerate the development of new drugs and increase the success rate through strategic cooperation research with domestic and overseas research institutes and pharmaceutical institutions. '

Daan Biotherapeutics

Seed Round in 2022
DAAN Biotherapeutics focuses on developing innovative cancer treatments, particularly for lung cancer. The company conducts research and development in immune-oncology, utilizing advanced strategies such as anticancer immune cell therapy that employs natural killer (NK) cells and T cell receptors. DAAN Biotherapeutics aims to create effective therapies by integrating various treatment modalities, including cell therapies, antibodies, and small molecule inhibitors. Their work involves conducting clinical trials based on independent research infrastructure, with the objective of providing healthcare providers with effective options for treating cancer patients.

Daim Research

Seed Round in 2022
DAIM Research is a company that specializes in AI-based automation solutions for logistics and manufacturing. It develops software designed to control and manage logistics robots, utilizing collaborative intelligence technology to enhance operational efficiency. By continuously monitoring these robots, the company ensures optimal performance, allowing businesses to innovate their manufacturing processes through the integration of data and artificial intelligence. This focus on automation and real-time management positions DAIM Research as a key player in transforming logistics and manufacturing systems.

KaliVir Immunotherapeutics

Series A in 2022
KaliVir Immunotherapeutics focuses on developing innovative oncolytic viral immunotherapy products aimed at treating various tumor types. The company utilizes a novel oncolytic vaccinia platform to enhance the systemic delivery of therapies through intravenous methods, ensuring targeted replication and effective viral spread within tumors. Their programs incorporate both in-house technologies and licensed advancements from the University of Pittsburgh, a leader in oncolytic virus and immunotherapy research. By leveraging proprietary genetic modifications, KaliVir aims to provide healthcare professionals with advanced treatment options that harness the body's immune response to combat cancer effectively.

OncXerna Therapeutics

Venture Round in 2022
OncXerna Therapeutics, Inc. is a biotechnology company focused on developing precision medicines for cancer patients by utilizing an RNA-based biomarker platform. The company aims to improve patient outcomes by prospectively identifying individuals based on the unique RNA biology of their tumor microenvironments. This innovative approach enables OncXerna to match patients with targeted oncology therapies that correspond to their specific tumor characteristics. Founded in 2018 and based in Waltham, Massachusetts, with an additional location in Shanghai, China, OncXerna was formerly known as Oncologie, Inc. and changed its name in September 2020 to reflect its commitment to advancing next-generation precision medicine for a broader range of cancer patients.

Neosapience

Series B in 2022
Neosapience, Inc. is a South Korean artificial intelligence company specializing in generative voice and avatar technologies. Founded in 2017 and headquartered in Seoul, the company has developed innovative software that learns individual voice features to generate speech that mimics a person's unique voice identity, prosody, and emotion. Among its offerings are Icepeak.AI, an online platform that creates voice replicas, and ICEPEAK, a mobile application that allows users to interact with characters that speak their inputted text. Neosapience's flagship product, Typecast, launched in 2019, has gained popularity as an AI-powered content creation service, utilized by over 2 million users across 225 countries. This platform enables users to produce audio and video content effortlessly by inputting scripts and leveraging AI-generated voices and avatars, thereby redefining the landscape of creative expression through advanced voice synthesis technologies.

HITS

Series A in 2022
HITS is a biotech company that creates digital solutions to accelerate drug development and introduce a new drug discovery paradigm. The company creates a cloud-based drug development platform that connects AI models with docking and molecular dynamics.

Rapport Labs

Series B in 2022
Rapport Labs is focused on enhancing the online shopping experience through its 4050 fashion platform, which is specifically designed to assist women in purchasing clothing. The platform features a wide range of apparel from established brands, catering to various age groups. It also offers discounts and includes a dedicated customer experience team that provides real-time support and fashion advice via phone calls and inquiries. This comprehensive approach aims to simplify the online shopping process and ensure that users can find their desired clothing efficiently.

Organoid Sciences

Series B in 2022
Organoid Sciences is a drug development company based in Seongnam-si, South Korea, founded in 2018. The company specializes in organoid-based treatments and utilizes cannabinoid-based technology to create drugs aimed at addressing various incurable diseases. In addition to drug development, Organoid Sciences provides drug screening services and focuses on regenerative medicine, contributing to advancements in healthcare solutions.

Amicogen

Post in 2022
Amicogen is an industrial biotechnology company based in Korea, specializing in the development, production, and distribution of bioproducts and health functional food ingredients. The company's diverse product portfolio includes special enzymes, N-acetylglucosamine, pinitol, D-Chiro-inositol, collagen peptides, and protein A chromatography resins. Additionally, Amicogen offers products such as endo-lac, ginseng extraction powder, cauliflower mushrooms, chitosan oligosaccharides, chitoslim, and keyclean, catering to the growing demand for innovative solutions in the health and wellness sectors.

Rapport Labs

Venture Round in 2022
Rapport Labs is focused on enhancing the online shopping experience through its 4050 fashion platform, which is specifically designed to assist women in purchasing clothing. The platform features a wide range of apparel from established brands, catering to various age groups. It also offers discounts and includes a dedicated customer experience team that provides real-time support and fashion advice via phone calls and inquiries. This comprehensive approach aims to simplify the online shopping process and ensure that users can find their desired clothing efficiently.

ViFiVE

Venture Round in 2022
ViFiVE is a software development company that has recently launched a patient app focused on remote therapeutic monitoring. The platform is designed specifically for individuals with musculoskeletal disorders, offering self-assessment tools to monitor health parameters. Through its application, ViFiVE enables users to track their compliance and outcomes effectively, promoting a healthier lifestyle. The company also provides an online inquiry form on its website for potential users and partners to engage with its services.

Tcino Bioscience

Venture Round in 2022
Tcino Bioscience develops molecule anti-cancer drugs for cancer patients.

Cinamon

Venture Round in 2022
Cinamon provides a visual story platform designed for casual games. In 2018, the company began as a joint venture with Naver Webtoon. Since our first project, an interactive stories app called "Maybe," the company has continued to broaden its scope in the field of visual storytelling. The company is currently working on two projects: a 2D and a 3D UGC story platform.

Anterogen

Post in 2022
Anterogen is a bio-venture company focused on the research and development of cell therapy products and orphan drugs utilizing adult stem cells. The company's product portfolio includes Cupistem injection, Queen cell, Remodulin injection, and TheraStem-Derma. In addition to its therapeutic offerings, Anterogen provides cell banking services and analytical services, which include sample analysis for clinical studies. Through its innovative approaches, Anterogen aims to advance treatments in the field of regenerative medicine.

Markoville

Venture Round in 2022
Markoville is an entertainment content company that creates a character for animation, game, and comics.

HITS

Venture Round in 2022
HITS is a biotech company that creates digital solutions to accelerate drug development and introduce a new drug discovery paradigm. The company creates a cloud-based drug development platform that connects AI models with docking and molecular dynamics.

StyleC

Series B in 2021
StyleC is an online marketplace that specializes in a diverse selection of products for personal and home use. The platform offers a wide range of categories, including furniture, clothing, cosmetics, accessories, and books, allowing customers to access various items tailored to their needs. By providing a centralized shopping experience, StyleC aims to simplify the purchasing process for consumers seeking quality products.

Path

Seed Round in 2021
Path provides an AI platform for managing study habits. The startup employs deep learning-based to give non-face-to-face real-time academy lectures for middle and high schools, with the goal of changing the digital education platform.

Nota AI

Series B in 2021
Nota AI is a technology startup specializing in artificial intelligence model optimization. The company has developed a proprietary platform, NetsPresso, which is designed to optimize AI models for specific hardware, thereby reducing the time and resources needed for development. This optimization allows various industries, such as intelligent transportation systems and low-powered driver monitoring systems, to implement enhanced AI solutions tailored to their specific needs. Through its innovative approach, Nota AI aims to facilitate the efficient deployment of AI technologies across diverse applications.

WAUG

Series C in 2021
WAUG Travel Inc. is a prominent online platform that facilitates the reservation of tours and activities for travelers. It allows users to easily create travel itineraries and book various experiences, ranging from museum visits and theme park excursions to extreme activities, through both mobile and web interfaces. The platform is designed to help users search for options, check availability, compare prices, and ultimately discover new destinations for their adventures around the globe.

Getcha

Series A in 2021
Getcha operates as a comprehensive online platform for car purchasing, long-term rentals, leasing, test rides, and car consulting. The company connects buyers with sellers through a comparison shopping service, allowing consumers to access a network of dealerships and obtain multiple price quotes. This transparency in transaction pricing empowers consumers to make informed decisions while enabling sellers to concentrate on potential buyers. By streamlining the car buying and renting process, Getcha aims to enhance the overall experience for both consumers and sellers in the automotive market.

Balaan

Series B in 2021
Balaan is an online marketplace that specializes in providing access to luxury fashion products, including clothing, accessories, and jewelry from renowned brands. By partnering with local boutiques in Europe, Balaan ensures that customers can receive the latest luxury items within three days at competitive prices, making high-end fashion more accessible. The platform aims to cater to both men and women, offering a diverse selection of multi-branded goods that appeal to fashion enthusiasts looking for quality and affordability.

afun interactive

Series B in 2021
Afun Interactive Inc. is a virtual reality company based in Seoul, South Korea, founded in 2016. The company specializes in three-dimensional rendering technologies and produces real-time content for various applications, including augmented reality and virtual reality. It focuses on creating and distributing digital content tailored to the unique needs of its clients, serving both the entertainment industry and other sectors that require advanced 3D animations and graphics. Through its expertise in real-time rendering technology, Afun Interactive aims to innovate and enhance the user experience in digital environments.

Bankware Global

Series B in 2021
Founded in 2010 and headquartered in Seoul, Korea, Bankware Global is a banking software developer that specializes in providing core banking solutions and financial software systems. The company serves a diverse clientele, including retail, corporate, private, treasury, fund administration, microfinance, and community banks, with over 100 financial institutions across seven countries in the Asia Pacific region. Notably, five digital banks in Korea, China, Japan, and Taiwan utilize Bankware Global's core banking software, highlighting the company's reputation as a leading provider in this sector. With offices in three countries, Bankware Global is recognized for its expertise in creating comprehensive financial institution products and transaction business software tailored for both domestic and international markets.

Upstage

Series A in 2021
Upstage AI is a startup that specializes in providing customized artificial intelligence services to businesses. The company develops tailored AI models designed to address specific challenges faced by its clients, thereby enhancing operational efficiency and fostering innovation. By enabling organizations to focus on their core tasks, Upstage AI helps them leverage AI technology to solve problems and advance their business processes effectively.

WAVEPIA

Series A in 2021
WAVEPIA is a semiconductor manufacturing company.

Tcino Bioscience

Series A in 2021
Tcino Bioscience develops molecule anti-cancer drugs for cancer patients.

J2H Biotech

Venture Round in 2021
J2H Biotech is a bio-venture company dedicated to the development of small-molecule drugs aimed at treating rare and challenging diseases. The company focuses on enhancing the oral absorption rates of its synthetic drugs and employs innovative patent-linked systems to facilitate the availability of generic medications for conditions such as intractable rare diseases, infectious diseases, and liver diseases. By advancing these therapeutic alternatives, J2H Biotech seeks to improve patient outcomes and expand treatment options for healthcare providers.

Return Zero

Series B in 2021
Return Zero, Inc. is a company that specializes in developing an artificial intelligence-based voice recognition application designed to convert phone dialogues into messenger chats. Founded in 2011 and based in Seoul, South Korea, the company offers services that transform audio phone messages into text, facilitating easier communication through messaging platforms.

Pharos iBio

Series C in 2021
Pharos iBio Co. is a biotechnology company focused on the development of innovative treatments for rare and intractable diseases. Leveraging a novel drug development platform that incorporates big data and artificial intelligence technology, the company aims to address significant medical needs. Among its product candidates are PHI-101-AML, targeting refractory or relapsed acute myeloid leukemia; PHI-101-OC, designed for patients with platinum-resistant or refractory ovarian cancer; and PHI-101-TNBC, aimed at treating metastatic triple-negative breast cancer. Additionally, the company is advancing several other candidates, including PHI-201, PHI-301, and PHI-501. Through its targeted approach, Pharos iBio seeks to contribute to the advancement of treatment options in oncology.

Rapport Labs

Series A in 2021
Rapport Labs is focused on enhancing the online shopping experience through its 4050 fashion platform, which is specifically designed to assist women in purchasing clothing. The platform features a wide range of apparel from established brands, catering to various age groups. It also offers discounts and includes a dedicated customer experience team that provides real-time support and fashion advice via phone calls and inquiries. This comprehensive approach aims to simplify the online shopping process and ensure that users can find their desired clothing efficiently.

Rapport Labs

Series A in 2021
Rapport Labs is focused on enhancing the online shopping experience through its 4050 fashion platform, which is specifically designed to assist women in purchasing clothing. The platform features a wide range of apparel from established brands, catering to various age groups. It also offers discounts and includes a dedicated customer experience team that provides real-time support and fashion advice via phone calls and inquiries. This comprehensive approach aims to simplify the online shopping process and ensure that users can find their desired clothing efficiently.

Kmong

Series C in 2021
Kmong Inc. is a South Korean company that operates a freelance and micro-job marketplace, facilitating the exchange of services between individuals. Established in June 2012, the platform allows users to buy and sell a wide range of services across various categories, including design, IT and programming, marketing, consulting, translation, writing, and more. Freelancers can list their services with price quotes, making it easier for potential clients to find and engage with them. Kmong's services extend beyond traditional categories to include offerings like private lessons and unique personal services. The company is based in Seoul and provides a mobile application for Android devices, enhancing accessibility for users.

Databank

Series A in 2021
Databank is an AI-driven EdTech startup focused on enhancing education through innovative online test preparation services. By utilizing advanced machine learning and deep learning algorithms, Databank addresses the knowledge gap in education. The company's AI-powered solution evaluates open-ended responses from students and delivers personalized instructional content tailored to individual learning needs. This approach not only aids students in their test preparation but also aims to create a broader social impact within the education sector.

Databank

Series A in 2021
Databank is an AI-driven EdTech startup focused on enhancing education through innovative online test preparation services. By utilizing advanced machine learning and deep learning algorithms, Databank addresses the knowledge gap in education. The company's AI-powered solution evaluates open-ended responses from students and delivers personalized instructional content tailored to individual learning needs. This approach not only aids students in their test preparation but also aims to create a broader social impact within the education sector.

Pin Therapeutics

Venture Round in 2021
Pin Therapeutics, Inc. is a biotechnology company founded in 2017 and based in South San Francisco, California. The company specializes in developing therapeutic products that utilize protein degradation technology to target and break down disease-causing proteins. Pin Therapeutics focuses on treating immune diseases, cancer, and age-related conditions. Its drug discovery efforts include programs centered on novel molecular glue degraders and a PROTAC program, aimed at addressing specific medical needs and enhancing treatment efficacy. The company employs a diverse team of scientists and leaders with experience from global pharmaceutical and biotech firms, and it operates with a notable presence in both the United States and Korea. Pin Therapeutics is committed to advancing drug discovery through innovative screening systems and platforms that improve biological specificity for targeted protein degradation.

Zymedi

Venture Round in 2021
Zymedi is a pharmaceutical company dedicated to developing innovative therapeutics for life-threatening diseases. The company focuses on creating treatments that improve the quality of life for patients suffering from conditions such as pulmonary arterial hypertension and liver fibrosis. Utilizing a novel platform centered on aminoacyl-tRNA synthetases, Zymedi aims to expedite the treatment process for patients, thereby enhancing medical outcomes.

Innovo Therapeutics

Venture Round in 2021
Innovo Therapeutics is focused on advancing drug discovery through its artificial intelligence platform, DeepZema. This proprietary technology integrates practical drug development experience with virtual discovery, leveraging machine learning for target identification and toxicity prediction. Innovo Therapeutics aims to enhance the quality of human life by developing new treatments for conditions such as fibrosis and immune and inflammatory diseases, ultimately supporting healthcare professionals in providing effective therapies.

TCUBEit

Venture Round in 2021
TCUBEit Inc. is a biotechnology company based in Sejong, South Korea, with an additional location in Cheongju. Founded in 2019, TCUBEit specializes in T cell-based immunotherapy, focusing on the collection and organization of T cells from patients. The company is dedicated to enhancing both the quantity and quality of T cells, which play a crucial role in identifying and eliminating cancers and infections in the human body. Moreover, TCUBEit is involved in the research, development, and commercialization of T-cell receptor-based cellular therapeutics, facilitating the discovery of innovative personalized therapies for cancer treatment.

S&E bio

Venture Round in 2021
S&E Bio is a biopharmaceutical company dedicated to developing cell therapies specifically designed to treat neurological disorders. The company focuses on creating safe and effective treatments using stem cell-derived extracellular vesicles. Its innovative approach targets various conditions, including acute stroke, moyamoya disease, chronic stroke, dementia, and cognitive disorders. By leveraging mesenchymal stem cell-derived therapeutics, S&E Bio aims to provide advanced treatment options for patients suffering from these challenging and often incurable diseases.

Prazer Therapeutics

Venture Round in 2021
Prazer Therapeutics is a biotechnology company dedicated to developing novel therapeutics for patients suffering from intractable diseases, particularly focusing on neurodegenerative and refractory inflammatory conditions. The company employs innovative drug design approaches, including rational molecular drug design and next-generation protein degradation technology, to create effective treatments. By leveraging these advanced platforms, Prazer Therapeutics aims to address significant unmet medical needs and enhance the treatment landscape for challenging health issues.

Promedigen

Venture Round in 2021
Promedigen is a biotechnology company that specializes in developing treatments for cancer and neurodegenerative disorders. The company focuses on customized modified protein technology, which facilitates the production of abnormally modified proteins linked to various serious diseases. This innovative approach aims to enhance the effectiveness of treatments for conditions such as cancer and dementia, thereby improving patient outcomes. Promedigen's commitment to addressing these challenging health issues positions it as a significant player in the biotechnology sector.

Watcha

Venture Round in 2020
WATCHA, Inc. is a South Korean company that specializes in online interactive media services, primarily through its movie and TV series recommendation application. Launched in 2012, WATCHA quickly gained popularity in Korea as a leading movie review app, leveraging personalized recommendation technology to suggest films based on user ratings. The platform not only offers extensive movie and TV show reviews but also includes WATCHA PLAY, a subscription-based video-on-demand service launched in 2016. This service is accessible on various devices, including web browsers, mobile applications, and smart TVs. With a strong focus on accurate content recommendations, WATCHA claims that 75% of the content consumed on its platform is based on user-generated recommendations. The company, headquartered in Seoul, has also expanded its offerings to Japan, enhancing its position in the competitive media landscape.

HaplnScience

Seed Round in 2020
HaplnScience is a pharmaceutical company based in Seongnam-si, Gyeonggi-do, South Korea, founded in 2018. The company specializes in developing innovative anti-aging therapies aimed at reversing tissue and organ degeneration. Utilizing HAPLN1, a novel protein, HaplnScience's medications strengthen the extracellular matrix, which is crucial for maintaining healthy tissues. Their products are designed to prevent degeneration in various body tissues, addressing issues such as skin and hair aging, as well as effectively treating conditions like osteoarthritis. By focusing on these advancements, HaplnScience aims to enhance the health and quality of life for the elderly.

CHAI

Series B in 2020
CHAI is a company focused on developing infrastructure technologies aimed at enhancing the efficiency of the digital economy. It offers a fintech platform that includes a debit card, a merchant-facing payment API, and an e-wallet that utilizes blockchain technology. This platform allows merchants and individual users to integrate a diverse array of payment options quickly and easily, often in less than an hour. Users can pay for items online by linking their bank accounts, streamlining the payment process. Through its innovative solutions, CHAI aims to facilitate seamless financial transactions and improve the overall digital payment landscape.

MediBloc

Series A in 2020
MediBloc is a decentralized healthcare information ecosystem that leverages blockchain technology to empower patients, healthcare providers, and researchers with ownership and control over medical data. The platform facilitates secure storage and transfer of medical records, allowing rightful owners to manage their information effectively. By providing data input and output capabilities, as well as interfaces for third-party applications and services, MediBloc enables the development of various healthcare solutions that utilize medical data. This innovative approach aims to revolutionize global healthcare by enhancing data accessibility, improving care quality, and minimizing medical errors.

Olix Pharmaceuticals

Post in 2020
OliX Pharmaceuticals is a clinical stage biotechnology company based in Suwon, South Korea, specializing in the development of RNA interference (RNAi) therapeutics aimed at treating dermal, ophthalmic, and pulmonary diseases. The company's product pipeline includes several innovative treatments such as OLX101 for skin scars, OLX102 for skin whitening, OLX103 for atopic dermatitis, OLX104 for hair loss, and OLX105 for anti-wrinkle applications. Additionally, it is working on OLX106 for diabetic foot ulcers, OLX301 for age-related macular degeneration, OLX304 for retinitis pigmentosa, OLX201 for lung fibrosis, OLX202 for asthma, OLX203 for influenza, and OLX401 for neuropathic pain. The company also has a collaboration with Théa to develop SiRNA therapeutics specifically for ophthalmic diseases. Founded in 2010, OliX Pharmaceuticals leverages its proprietary RNAi technology to regulate the expression of genes associated with various diseases.

My Franchise

Series A in 2020
My Franchise is a company founded in 2019 in Seoul, South Korea, that addresses the information gap between franchise headquarters and potential founders. It operates an online platform that facilitates connections between these two parties, optimizing their partnership potential. The platform offers valuable insights for prospective founders, including data on the number of franchisees by year, average sales figures, and start-up costs associated with domestic franchise brands. This allows users to effectively compare and analyze important brand information across various industries, enabling informed decision-making for franchise investments.

Wave

Series B in 2020
Wave Corporation, founded in 2018 and based in South Korea, develops a mobile video chat application designed to enhance social interactions among users. The application enables individuals to create chat rooms where they can engage in group video chats, play live party games, watch video clips, read webtoons, and share photos. By facilitating these activities, Wave aims to reduce the distance between people, allowing friends to connect and interact in a more engaging and entertaining manner.

Innospace

Series A in 2020
Innospace is an aerospace and defense company focused on developing hybrid rocket-powered small satellite launch vehicles. The company aims to provide cost-effective, low-latency, and environmentally friendly launch services tailored for the small satellite market. By utilizing innovative hybrid rocket technology, Innospace is committed to delivering reliable solutions for satellite deployment, catering to the increasing demand for efficient access to space.

Cimplrx

Series A in 2020
Cimplrx is a health technology company that specializes in drug discovery by utilizing explainable artificial intelligence. Its platform offers a comprehensive database that includes information on both new drug discoveries and existing medications available in the market. Cimplrx provides clients with tools to analyze and visualize the drug discovery process, enabling them to form effective business models. The company's focus on artificial intelligence enhances its capabilities in discovering and developing drug candidates, making it a valuable resource in the pharmaceutical industry.

Immunobiome

Series A in 2020
Immunobiome focuses on developing microbiome-targeted therapeutics aimed at treating challenging conditions such as cancer, autoimmune diseases, and neurological disorders. The company leverages advanced immunology, bioinformatics, and foundational microbiome research to create innovative healthcare solutions. Their platform addresses a range of health issues, including intractable immune disorders, allergies, organ transplant rejections, and diabetes-related inflammation. By targeting the microbiome, Immunobiome seeks to provide effective treatment options for patients suffering from these complex diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.